| Gene Symbol | BIOMARKERS |
| Diagnostic accuracy | Clinical syndromes in FTLD overlap significantly, making pathology prediction challenging based on symptoms alone |
| Clinical trial enrichment | Targeted therapies will require enrichment of patients with the correct underlying pathology |
| Prognostic information | Different FTLD subtypes have varying disease trajectories and respond differently to emerging treatments |
| Genetic counseling | Certain genetic mutations (e.g., MAPT for tau, GRN or C9orf72 for TDP-43) correlate with specific pathologies |
| Neurofilament light chain (NfL) | Elevated in both subtypes but higher in FTLD-TDP[@khalil2023] |
| Progranulin | Reduced in GRN mutation carriers (FTLD-TDP) |
| NPTX2 | Neuronal pentraxin, potentially reduced in FTLD-TDP |
| p-tau181 + NfL | Improves discrimination beyond single markers |
| p-tau181 + progranulin | Accounts for GRN mutations |
| ATN framework adaptation | A (amyloid), T (tau), N (neurodegeneration) applied to FTLD |
| Associated Diseases | Neurocognitive Disorders, Prostate Cancer, ALS, Frailty, Hepatocellular Carcinoma, Inclusion Body Myositis |
| KG Connections | 2 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!